BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cabotegravir/rilpivirine (Cabenuva) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cabotegravir/rilpivirine (Cabenuva)\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06411223-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 2 readout est. (NCT06411
 223)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 2\, HIV.\nStudy: Ph
 armacist-led Intervention for Injectable HIV Treatment for Women With Heal
 th-related Social Needs\nEstimated primary completion: March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpivirine-cab
 enuva#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06411223
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06786520-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 1 readout est. (NCT06786
 520)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 1\, HIV.\nStudy: A 
 Study to Evaluate the Pharmacokinetics\, Safety\, and Tolerability of Cabo
 tegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Lo
 ng-acting (CAB LA) in Healthy Adults\nEstimated primary completion: 8 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-
 rilpivirine-cabenuva#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06786520
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05044962-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase na readout est. (NCT0504
 4962)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase na\, HIV.\nStudy: K
 uwa Free! - Live Free!\nEstimated primary completion: 31 March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpivirine-c
 abenuva#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05044962
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646562-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 4 readout est. (NCT06646
 562)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 4\, HIV.\nStudy: Lo
 ng Acting Cabotegravir Plus Rilpivirine in People Living With HIV-1 Aged 
 ≥ 60 Years for 24 Months.\nEstimated primary completion: 30 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpiviri
 ne-cabenuva#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06646562
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05418868-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 1 readout est. (NCT05418
 868)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 1\, HIV.\nStudy: A 
 Study to Investigate Pharmacokinetics\, Safety and Tolerability of Long-Ac
 ting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adu
 lt Participants\nEstimated primary completion: 31 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 18868
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637942-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20280422
DTEND;VALUE=DATE:20280423
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 4 readout est. (NCT07637
 942)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 4\, HIV.\nStudy: Ca
 botegravir & Rilpivirine Antiretroviral Therapy in Pregnancy\nEstimated pr
 imary completion: 22 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07637942
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727642-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase na readout est. (NCT0772
 7642)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase na\, HIV.\nStudy: O
 ptimization of Antiretroviral Therapy in Patients With AIDS-Related Lympho
 ma\nEstimated primary completion: July 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07727642
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650916-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 3 readout est. (NCT07650
 916)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 3\, HIV.\nStudy: A 
 Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivi
 rine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Ar
 e Virologically Suppressed\nEstimated primary completion: 13 August 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpivir
 ine-cabenuva#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07650916
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939529-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 1 readout est. (NCT07939
 529)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 1\, HIV.\nStudy: Pe
 ople With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegr
 avir for Effectiveness\nEstimated primary completion: 31 August 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpivirine-
 cabenuva#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07939529
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275606-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20291010
DTEND;VALUE=DATE:20291011
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 1/2 readout est. (NCT072
 75606)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 1/2\, HIV.\nStudy: 
 A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1\nEstimat
 ed primary completion: 10 October 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07275606
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816250-957@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20320610
DTEND;VALUE=DATE:20320611
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 2 readout est. (NCT07816
 250)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 2\, HIV.\nStudy: A 
 Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectabl
 e Plus Cabotegravir in Treatment Naïve Adults (CINERGY)\nEstimated primar
 y completion: 10 June 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cabotegravir-rilpivirine-cabenuva#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07816250
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
